OrbusNeich said today it launched a Chinese trial of its Combo dual-therapy coronary stent designed to repair vessel injury and regenerate endothelium. The 436-patient randomized, non-inferiority trial has enrolled its 1st patient, the Hong Kong-based company said, and will compare the Combo stent’s effectiveness against Lepu Medical‘s Nano stent for up to 5 years. “We […]
OrbusNeich
OrbusNeich launches U.S. pivotal for Combo stent
OrbusNeich Medical said today that it enrolled the 1st U.S. patient in a pivotal trial of its dual-therapy Combo stent.
Echo Therapeutics in midst of a proxy battle with Platinum Management | Medtech personnel moves for the week of Apr. 28, 2014
Orthofix names interim CFO, taps CareFusion CFO for board | Personnel Moves
OrbusNeich launches Combo stent pivotal trial in bid for Japanese approval
OrbusNeich Medical said it launched a clinical trial in the U.S. and Japan for its Combo dual-therapy coronary stent as it gears up to apply for Shonin approval in Japan.
Boston Scientific settles stent patent spat with OrbusNeich
Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.
Boston Scientific legal update: Guidant, Guidezilla and ongoing arguments
Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.
Boston Scientific legal update: Ups and downs in tussles with Iraq, OrbusNeich and the feds
Boston Scientific (NYSE:BSX) is no stranger to the court room, and its latest quarterly release is a testament to the company’s legal tenacity.
OrbusNeich lands CE Mark for Combo dual-therapy stent
OrbusNeich Medical said it got the green light in Europe for its Combo dual-therapy stent, calling it the 1st such device to both promote healthy tissue growth and prevent the stent from being engulfed by tissue growth.